Charles Schwab Investment Management Inc. raised its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,230,087 shares of the conglomerate's stock after purchasing an additional 163,332 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.59% of Danaher worth $867,168,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its stake in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter worth approximately $27,000. Sierra Ocean LLC raised its stake in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher in the 1st quarter valued at $31,000. Finally, Dunhill Financial LLC increased its stake in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Stock Performance
Shares of NYSE DHR traded up $2.21 during mid-day trading on Friday, hitting $200.70. The company had a trading volume of 2,963,091 shares, compared to its average volume of 4,823,699. The stock has a market cap of $143.71 billion, a price-to-earnings ratio of 42.70, a PEG ratio of 2.80 and a beta of 0.73. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm's 50 day simple moving average is $198.46 and its two-hundred day simple moving average is $200.94.
Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.72 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.
Insider Buying and Selling
In related news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on DHR. Leerink Partners raised their price objective on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Wells Fargo & Company lowered their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Jefferies Financial Group decreased their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Finally, JPMorgan Chase & Co. cut their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $247.61.
Read Our Latest Stock Analysis on DHR
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also

Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.